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Available online 2 May 2008HIV-1 manipulates cellular machineries such as cyclin dependent kinases (cdks) and their cyclin elements, to
stimulate virus production and maintain latent infection. Speciﬁcally, the HIV-1 viral protein Tat increases
viral transcription by binding to the TAR promoter element. This binding event is mediated by the
phosphorylation of Pol II by complexes such as cdk9/Cyclin T and cdk2/Cyclin E. Recent studies have shown
that a Tat 41/44 peptide derivative prevents the loading of cdk2 onto the HIV-1 promoter, inhibiting gene
expression and replication. Here we show that Tat peptide analogs computationally designed to dock at the
cyclin binding site of cdk2 have the ability to bind to cdk2 and inhibit the association of cdk2 with the HIV
promoter. Speciﬁcally, the peptide LAALS dissociated the complex and decreased kinase activity in vitro. We
also describe our novel small animal model which utilizes humanized Rag2−/−γc
−/− mice. This small peptide
inhibitor induces a decrease in HIV-1 viral transcription in vitro and minimizes viral loads in vivo.
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Human immunodeﬁciency virus (HIV-1) is the etiological agent of
acquired immunodeﬁciency syndrome (AIDS). Approximately 40 mil-
lion people are currently infected with HIV-1 and 4 million new cases
will be identiﬁed this year alone. When administered properly, the
currently available HIV-1 medications are capable of controlling in-
fection, however they do not represent a cure. Highly active antire-
troviral therapy (HAART) is currently themosteffective strategy inHIV-1
treatment and reduction in AIDS-related mortality. HAART is a multi-
drug therapywhichhas proven to beeffective in loweringviral loads and
improving the host immune response to HIV-1 infection. While the
drugs merely prevent infection of new cells, latently infected cellsniversity, School of Medicine,
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nc.continue to produce varying levels of wild type and mutant viruses.
Additionally, the currently available drugs speciﬁcally target viral
proteins, such that small polymorphisms largely affect the efﬁciency of
drug action. The high rate ofmutation caused by the viral RTenzyme, for
example, and the large numbers of new virus produced during each
round of infection allow the virus to select variants with mutations that
make them resistant to currently available therapies.
Current therapies in HIV-1 are insufﬁcient due to their inability to
cure the disease and the proﬁciency of the virus to become resistant to
the treatmentover time. New therapiesmust be developedwhich target
novel mechanisms important to the viral life cycle. HIV encodes only
nine genes; a fact which forces the virus to interact with and subvert
cellular processes for its own beneﬁt. Identifying these interactions and
their effect on both the virus and the cell will reveal a new range of
targets for future therapeutics. Alternative preventative measures such
as topical microbicides and vaccines are in development, however the
rate at which HIV-1 can replicate and mutate forces the need for an in
depth understanding of the viral/host cell relationship.
Tat is the HIV-1 viral transactivator protein responsible for tran-
scriptional activation and elongation. Tat has been known to not only
stimulate the HIV long terminal repeat (LTR) promoter, but also to
Fig. 1. Computational modeling of Tat analogs in the cyclin binding site of cdk2. An example of a three dimensional ligand binding model of a Tat peptide analog in the cdk2 binding
site. Cdk2 is shown as a ribbon model where the secondary structure elements are indicated by arrows (β-sheets) and spirals (α-helices) and is colored from the N-terminus (blue) to
the C-terminus (red). A Tat peptide is shown bound to cdk2 in a ball and stick conﬁguration and colored based on amino acid residue. Computational modeling was performed to
predict the binding afﬁnities of the Tat derived analogs to the cyclin binding site of Cdk2. Peptides designed for the purpose of this study were chosen based on stronger binding
afﬁnities than the TAALS peptide published previously (Agbottah et al., 2006). The binding energies are expressed in kcal/mol.
Fig. 2. Immunoprecipitation of Cyclin E and Western blot for cdk2 and phosphorylated
cdk2 in the presence of Tat derived peptides. A) C81 fractionated cell extracts containing
cdk2/Cyclin E were incubated with α-Cyclin E antibody in the presence of Tat derived
peptides. Following pull-down samples were probed for both unphosphorylated and
phosphorylated cdk2. Various competing peptides at 10 μg/μl/reaction were added at
the time of immunoprecipitations. The wild type Tat sequence TKALG and IgG were
included as negative controls (data not shown). B) cdk2/Cyclin E were puriﬁed from
lysates of SF9 insect cells infected with baculoviruses producing cdk2 and Cyclin E as
described in Materials and methods. Purity of cdk2/Cyclin E (Sephadex H200 column)
was checked on 12% PAGE followed by Coomassie staining. cdk2/Cyclin E complex were
used in immunoprecipitation with anti-cdk2 antibody (10 μg) and the pulled-down
complex were incubated with various peptides (10 μg) for 4 h at 37 °C. Following the
incubation, samples were spun down and supernatants were used forWestern blot with
anti-cyclin E antibody (1:1000 dilution). C) Puriﬁed GST-cdk2 and GST-cdk4 (2 μg of
each double puriﬁed protein) were bound to the LAALS peptide (50 μg) overnight and
subsequently washed with a low stringent buffer (TNE50+0.01% NP-40). Any bound
peptides were then eluted using the same binding buffer plus 0.01% SDS. Eluted peptide
samples were combined with MS washing buffer and injected into an ESI-MS LCQ Deca
XPPlus Thermo Finnigan mass spectrometer at 10 μl/min and read through an API source.
Spectra were normalized to the highest abundant mass peak and were averaged over
the course of injection. Data acquisition and peak analysis were performed through the
Xcalibur software platforms. Data is shown zoomed in on relevant m/z ranges.
309R. Van Duyne et al. / Virology 376 (2008) 308–322modulate and induce cellular genes. Historically, the mechanism of
action by Tat has been assigned to the level of initiation and elongation
(Bohan et al., 1992; Brady and Kashanchi, 2005; Feinberg et al., 1991;
Kato et al., 1992; Laspia et al., 1989; Marciniak et al., 1990; Marciniak
and Sharp, 1991). Tat primarily activates the HIV LTR by binding to
the TAR element, an RNA stem-loop structure, which facilitates elon-
gation and recruitment of cellular factors. One of these cellular factors,
p-TEFb, a protein kinase composed of cdk9 and Cyclin T1, is activated
by Tat, resulting in hyper-phosphorylation of the large subunit of the
RNA polymerase II CTD and activation of transcription elongation
(Chiang and Roeder, 1995; Dal Monte et al., 1997; Garcia-Martinez et
al., 1997; Jeang et al., 1993; Kashanchi et al., 1996, 1994; Kim et al.,
2002; Richter et al., 2002; Roebuck et al., 1997; Veschambre et al.,
1995;Wei et al., 1998; Yu et al., 1995). In recent years Tat has also been
shown to bind a number of other factors which regulate chromatin
structure at the HIV promoter as well as enzymes that phosphorylate
the large subunit of RNA Pol II resulting in efﬁcient elongation of
transcription, such as CBP/p300 (Bieniasz et al., 1999; Deng et al.,
2000, 2001; Herrmann and Mancini, 2001; Herrmann and Rice, 1995;
Yang et al., 1997; Zhu et al., 1997). In addition to controlling the
functional modiﬁcations associated with viral transcription, Tat also
undergoes post-translational modiﬁcations by host cellular proteins.
For instance, it has been shown that Tat is acetylated at lysine 28 and
50, ubiquitinated at lysine 71, and methylated at arginine residues
(Boulanger et al., 2005; Bres et al., 2003, 2002).
Cyclin-dependent kinases (cdks) and their corresponding catalytic
Cyclin subunits are crucial regulators of eukaryotic cell cycle
progression. These cdk/Cyclin complexes positively assist the cell
cycle by aiding the progression through the G1/S and G2/M cell cycle
checkpoints. Speciﬁcally, the progression through the G1/S checkpoint
is managed by the phosphorylation of the retinoblastoma (Rb) protein
by the cdk2/Cyclin E complex (Athanassiou et al., 2004). The G1/S
checkpoint plays a key role in HIV-1 viral replication and in the
transcription of proliferative genes, in that immediately following this
cell cycle stage viral replication is dramatically increased (Athanassiou
et al., 2004). This suggests that the regulation of kinase activity of
complexes such as cdk2/Cyclin E complex play a role in Tat activated
transcription. Along these lines, Tat recruits the p-TEFb and cdk2/
Cyclin E complexes to the viral promoter allowing phosphorylation of
RNA Pol II CTD (Herrmann and Rice, 1995; Nekhai et al., 2002; Parada
and Roeder, 1996; Pumfery et al., 2003; Roebuck et al., 1997; Zhou
et al., 2004). Deng et al. have shown that Tat stimulates the phos-
phorylation of the CTD by interacting with cdk2/Cyclin E. Moreover,
the depletion of the cdk2/Cyclin E complex fromHeLa nuclear extracts
completely blocked Tat-dependent viral transcription (Deng et al.,
2002). Therefore, cdk2/Cyclin E is necessary for the phosphorylation ofthe CTD and consequently for Tat-activated viral transcription (Am-
mosova et al., 2006; Nekhai et al., 2000, 1997, 2002). Additionally, it
was observed that cdk2/Cyclin E exhibited an increase in kinase
activity in latently infected cells due to the loss of the cdk inhibi-
tor, p21/waf1. Further evidence that cdk2 is an important regulator of
HIV-1 transcription was reported when Tat itself was found to be
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Fig. 3. Loss of kinase activity of cdk2/Cyclin E in the presence of competing peptides.
Immunoprecipitation of Cyclin E in the presence of Tat peptides was performed as
described in Materials and methods. Immunoprecipitated Cyclin E samples in the
presence of Tat peptides were assessed for kinase activity by washing the beads with
kinase buffer to equilibrate the reaction. Histone H1 (5 μg/reaction) was added to each
reaction tube along with 2 μl of (γ-32P) ATP (3000 Ci/mmol). Reactions were incubated
at 37 °C for 30 min and stopped by the addition Laemmli buffer. The samples were
separated on a 4–20% Tris–Glycine gel. Top panel represents samples ran on gel, dried
and exposed to a PhosphorImager cassette and analyzed utilizing Molecular Dynamic's
ImageQuant Software. Bottom panel represents samples that were stained with
Coomassie blue, destained, and then dried for 2 h. Lane 2 served as a positive control
(100%) activity without any competing peptides.
311R. Van Duyne et al. / Virology 376 (2008) 308–322phosphorylated by cdk2 in vitro (Deng et al., 2002; Nekhai et al.,
2000). siRNA against cdk2 was also found to inhibit Tat-induced HIV-1
transcription and viral replication indicating that cdk2 is crucial for
viral progression (Ammosova et al., 2005). Finally, cdk2 was found to
be non-essential for normal host cell proliferation as evident by the
viability of cdk2 knock-out mice (Malumbres et al., 2003). Therefore,
the inhibition of the cdk2/Cyclin E complex is an appealing target for
HIV-1 anti-viral therapies.
Previously, we have shown that a Tat peptide (41/44) from the
HIV-1 core domain can inhibit HIV-1 gene expression and act as a
replication inhibitor (Agbottah et al., 2006). This Tat peptide
was synthesized by truncation of the sequences from both the N-
and C-terminus of Tat and included speciﬁc double mutations. This
condensed analog retained the speciﬁcity necessary to inhibit HIV-1
viral transactivation, and not other viral promoters from CMV or
HTLV-1. Furthermore this peptide was capable of inhibiting the
kinase activity of cdk2/Cyclin E in vitro (Agbottah et al., 2006; Deng
et al., 2002). Here we show a further reﬁnement of these peptides
using computational docking studies with the cdk2 structure,
therefore characterizing the cdk2/Cyclin E binding interface and
localizing potential dissociation sites both in vitro and in vivo. We
identiﬁed a new set of peptides that have better inhibitory effect on
activated transcription. These peptides also inhibit virus replication
in a new humanized stem cell animal model in vivo.
Results
Predicted binding energies of Tat peptide analogs
To better design peptides that could possibly bind or compete for
the Cyclin E and cdk2 interface, we ﬁrst utilized computational
docking models. Ligand candidates based on the Tat 41/44 mutant
peptide from the previous study were computationally designed as
indicated (Agbottah et al., 2006). Ligand candidates were prepared as
single mutations of TAALS, therefore, not straying too far from the
original Tat 41/44 sequence. Fig. 1 shows an example of a three
dimensional computational docking model of a small peptide and
cdk2. Here the structure of cdk2 is depicted in “ribbon” view such that
the secondary structure elements α-helices and β-sheets are depicted
as spirals and parallel arrows respectively. The cdk2 sequence is also
colored from blue to red to correspond to the N- and the C-termini
respectively. The small ligand in Fig. 1 is docked to the Cyclin binding
site of cdk2 and is represented in a “ball and stick” view. From energy
minimization studies, the afﬁnities of each ligand to the Cyclin binding
site of cdk2 were also determined. Each amino acid substitution
provides different bonding opportunities where each binding energy
is different. All of the newly proposed peptides have a higher
predicted binding afﬁnity than the Tat 41/44 peptide previously
described (Agbottah et al., 2006) with TAALD having the highest. This
suggests that these peptides may provide a higher percentage of
dissociation of the cdk2/Cyclin E complex.
Speciﬁcity of Tat peptide in possibly dissociating cdk2/Cyclin E complex
In order to detect any possible dissociation of the cdk2/Cyclin E
complex in the presence of the Tat peptides, immunoprecipitations of
Cyclin E were performed. Cell extracts were ﬁrst separated through a
size-exclusion column into various fractions (total of 80). A repre-
sentative amount of fractions were probed for cdk2 in order to
determine a size range in which the complex was likely to elute (data
not shown). This chromatographic step also minimized the chance
that non-speciﬁc binding interactions would occur with cdk/Cyclin
complexes. Also, in the previous Agbottah 2006 paper, we used
immunoprecipitations from HIV-infected whole cell extracts, where
the extracts contained two distinct populations of cdk2 complexes.
When using a sizing column, one population that is fairly large comesout at 440 kDa size and a second population elutes from 67 kDa up to
150 kDa. The smaller size complexes (67 kDa–150 kDa) are active cdk2
complexes whereas the large 440 kDa complex is largely inactive in
kinase activity and contains as yet unpublished proteins and RNA
bound molecules (Kashanchi and Nekhai, unpublished data; Deng
et al., 2002). Therefore, the smaller cdk2/Cyclin E containing fractions
(29–32) were pooled together and the extract (250 μg) was used in
immunoprecipitations with antibodies against Cyclin E in the
presence or absence of the Tat peptides. Immunoprecipitates (IPs)
were washed andWestern blotted for the presence of cdk2 and Cyclin
E. Results in Fig. 2A show the addition of six Tat derived peptides to the
IP reaction. Lanes 1 and 2 serve as controls for non-speciﬁc binding
and control IP reaction, respectively. There is a varying degree of
dissociation amongst the various Tat peptide competitors. For instance,
the LAALS peptide in lane 7 appears to have the highest level of
dissociation followed by TAACS. Based on the computational binding
energy prediction, it would have been assumed that TAALD would have
the highest efﬁciency of dissociation due to the strong binding afﬁnity
(lane 3), but the actual biochemical test (IP followed by competition)
showed a different result. Interestingly, the levels of detectable
phosphorylated cdk2 in these IP/competition experiments vary
depending on which peptide is used. For instance, LAALS and TAACS
peptides appear to have lower recovery levels of phosphorylated cdk2,
while the other peptides appear to have no effect on the basal recovery
levels of phosphorylated cdk2. Also, the lack of efﬁciency of competition
of the other peptides for cdk2 indicates that both unphosphorylated
and phosphorylated cdk2 can equally bind to Cyclin E as seen in the
immunoprecipitates.
We next asked if the new peptide derivatives could indeed
dissociate the cdk2/Cyclin E complex in vitro. We therefore used a
puriﬁed system where Baculovirus expressed cdk2/Cyclin E complexes
(Ammosova et al., 2006) were used in immunoprecipitation with anti-
cdk2 antibody and the pulled-down complexes were incubated with
various peptides for 4 h at 37 °C. Following the incubation, samples
were spun down and supernatants were used for Western blots with
anti-Cyclin E antibody. Results in Fig. 2B show that two peptides (TAALS
and LAALS), but not the wild type peptide (TKALG), were able to
dissociate the Cyclin E away from the cdk2 by about ~50% (compare
input level to lanes 2 and 3). These results further indicate that the new
LAALS peptide is able to at least partially dissociate the cdk2/Cyclin E
complex. Finally, we asked if we could indeed detect binding of the
LAALS peptide to the cdk2 protein in the absence of its cyclin partner.
Fig. 4. Cell cycle analysis of cells in the presence of Tat derived peptides. Cell cycle analysis was performed on CEM cells either untreated or treated withWTor Tat derived peptides. Cells were collected by low speed centrifugation and washed
with PBS without Ca2+ andMg2+ and ﬁxed with 70% ethanol. For ﬂuorescence-activated cell sorting (FACS) analysis, cells were stained with a mixture of propidium iodide (PI) solution for 30 min at room temperature prior to analysis. The cells
were acquired and analyzed using CELLQuest software (BD Biosciences). Acquired FACS data were analyzed byModFit LT software (Verity Software House, Inc.). Various panels represent: A) Untreated CEM cells, B) CEM cells treated with wild
type control peptide, C) TAALD, D) TAALE, E) TAACS, F) FAALS, G) LAALS, and H) TAALS. Percent of each cell populations in G1, S, G2/M, and apoptosis are indicated.
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313R. Van Duyne et al. / Virology 376 (2008) 308–322We designed an experiment where 2 μg of puriﬁed GST-cdk2
(experimental), and GST-cdk4 (control) were bound to the peptide
and subsequently washed with a low stringent buffer (TNE50+0.01%
NP-40). Any bound peptides were then eluted using the same binding
buffer plus 0.01% SDS. Eluted peptides from the supernatant were then
subjected to LCQ MS analysis (Thermo Finnegan) for detection. Results
of the experiment are shown in Fig. 2C, where the SDS buffer alone
shows a certain set of backgroundmolecularweight peaks (non-speciﬁc
peaks, i.e. 463.07, and 485.27). A similar set of peaks also showed up
(although with varying intensity) in the GST pull down experiment
(data not shown). However, the speciﬁc LAALS peptide appeared only in
the GST-cdk2 but not in the GST-cdk4 eluates, exhibiting a parent peak
of 474.3 Da. Other control experiments, including the use of wild type
peptides or Rb peptides which aren't normally phosphorylated by cdk2
exhibited no binding afﬁnity using this assay, however cdk9 boundFig. 5. Inhibition of HIV-1 transcription activity using transient transfection assay. Two pla
transfected either alone orwith various concentrations of wild type ormutant peptides (1, 5, a
protein extraction and CAT assay. Panel A shows wild type LTR activity by itself (lane 1) and w
(lanes 3–5) and mutant peptides (lanes 6–8) were all added at the time of transfection (elec
derivative (LAALS) in CATassay on HIV-1 LTR-CAT. Lane 3 and 5 were transfected with 1 μM an
experiment using HTLV-1 LTR-CAT (3 μg) and its transactivator CMV-Tax (1 μg) with either w
acetylated product over total 14C counts in each lanes. Panel D represents trypan blue exclusio
as positive control since it is known to modulate the p53 pathway and drive cells to apoptoequally well to this peptide (data not shown). Collectively, these results
imply that the LAALS is capable of binding to the cdk2 component of the
kinase complex.
Inhibition of cdk2/Cyclin E kinase activity in vitro
As seen previously, at least two of the Tat derived peptides have
been shown to dissociate the cdk2/Cyclin E complex as observed in the
Western blot analysis. Next, the functional kinase activity of cdk2/
Cyclin E in the presence of the inhibitors was measured. A radio-
actively labeled kinase assay was utilized to measure the levels of
phosphorylation of Histone H1 in the presence of these peptides.
Cyclin E immunoprecipitations were performed (similar to Fig. 2) and
the pull-downs were washed and used in a kinase reaction. Substrate
and radioactively labeled ATP were both added to the sample, and thesmids namely reporter HIV-1 LTR-CAT (3 μg) as well as CMV-Tat (1 μg) plasmids were
nd 10 μM). Transfected CEM cells were kept in completemedia for 48 h followed by total
ith Tat which activates the LTR promoter by more than 95% (lane 2). Wild type peptide
troporation). Panel B shows comparison of the old 41/44 peptide (TAALS) and the new
d lanes 4 and 6were transfected with 5 μMof each peptide. Panel C represents a similar
ild type peptide (lane 3) or LAALS peptide (lane 4) at 10 μM. Percent activity represents
n assay from cells transfected with 10 μMof each peptide for 72 h. Peptide p44was used
sis (Jalota-Badhwar et al., 2007).
Fig. 6. Effect of peptide inhibitor on HIV-1 infected latent cells. OM10.1 cells were ﬁrst
transfected with either TAALD or LAALS peptides (0.1, 1, 3 μM) and then treated cells
with TNF-α for 2 h. Samples were kept at 37 °C for 4 days prior to RT assay. Controls
included no peptide treatment, just TNF treatment or increasing concentration of cdk
inhibitor Cyc202 (panel A). Panel B represents trypan blue exclusion experiments that
utilized 5 μM of each reagent for up to 4 days. Two cell cycle inhibitors namely
Nocodazole (100 ng/ml) and hydroxyurea (5 mM) treatments were used as positive
controls for apoptosis after 4 days. Panel C represents Activated PBMCs that were
transfected with pNL4 with or without the two peptides. Cells were carried for up to
18 days and samples were collected at days 6, 12, and 18 for RT assay.
314 R. Van Duyne et al. / Virology 376 (2008) 308–322reactionmixture was incubated at 37 °C for 1 h. Finally, reactions were
terminated by the addition of SDS-loading buffer and loaded on a 4–
20% SDS/PAGE. Kinase activity was detected in the positive control
(Lane 2) and not the negative pulldown (Lane 1) in Fig. 3. Addition of
the peptides had varying effects on kinase activity. The lowest levels of
kinase activity can be seen where peptides LAALS and TAACS (Lanes 5
and 7) were added to the reaction as competitors. This indicates that
the peptides were able to possibly dissociate the cdk2/Cyclin E com-
plex enough to signiﬁcantly inhibit the catalytic activity on Histone
H1. It is important to note, however, that none of the peptides ever
completely dissociated the complex so that there was always some
residual kinase activity associated with the cdk2 in our assays. Col-
lectively, these data indicate that both LAALS and TAACS are able to
inhibit cdk2 kinase activity in vitro.
Cell cycle analysis of cells in the presence of inhibitory Tat peptides
Results from Fig. 3 indicated that there is high possibility that the
Tat peptides could dissociate the cdk2/Cyclin E complex in vitro and
therefore might interfere with cell cycle progression in vivo. To
address the possible cytotoxicity effects of these Tat peptides, we
utilized electroporation of peptides into CEM cells and cultured the
cells for 4 days. Treated CEM cells were then harvested, stained for cell
cycle, and analyzed by ﬂow cytometry (Fig. 4). Similar concentrations
of the peptides used in the kinase assay were used in electroporation
transfection assays. Interestingly, there is no real inhibitory effect on
cell cycle progression of these peptides in CEM cells as indicated by
similar populations of cells at G1, S, or G2/M phases. None of the
peptides induced a signiﬁcant amount of apoptosis or build up in any
one cell cycle stage. Therefore, the Tat peptides that compete and
inhibit kinase activity of the cdk2 in vitro are not toxic in an in vivo
functional assay.
Effect of Tat peptide inhibitor on HIV-1 transcription
Tat utilizes anumberof complexes including cdk2/Cyclin E (Agbottah
et al., 2006; Deng et al., 2002) to activate the HIV-1 LTR. We therefore
used an initial CAT reporter assay to determine the effects of Tat peptides
on Tat activation of the HIV-1 LTR. CEM cells were transfected, kept in
complete media for 48 h, lysed and used for CATassay. Results in Fig. 5A
show that Tat activates the LTR promoter by more than 95% (lane 2).
When using the wild type unmodiﬁed Tat peptide at 1, 5, and 10 μM no
change in Tat activated transcription was seen (lanes 3–5). However,
increasing concentration of LAALS peptide suppressed Tat activated
transcription (lanes 6–8). When compared to the parent 41/44 mutant,
the newpeptide LAALS showed better overall inhibition (panel B). Using
similar transfection experiments, the TAALS peptide at 5 μM inhibited
activity by 50% (lane 4) whereas the same concentration of LAALS
peptide inhibited the Tat activated transcription bymore than 90% (lane
6). Finally, the inhibitionwas speciﬁc toTat activation, since usingHTLV-
1 Tax and each of the peptides at high concentration (10 μM) did not
inhibit Tax activated HTLV-1 promoter activity (panel C). More
importantly neither of the peptides at 10 μM concentration shows any
signs of toxicity in CEM cells up to 72 h (panel D). A positive control P44
peptide which reactivates p21/waf1 (Jalota-Badhwar et al., 2007)
inhibited cell cycle progression and apoptosis as observed in a trypan
blue assay. Therefore, these results collectively indicate that Tat peptide
derivative LAALS inhibits HIV-1 activated transcription by Tat in tran-
sient transfected assays.
Effect of peptide inhibitor on HIV-1 infected latent cells
Next, we asked if the LAALS sequence was capable of suppressing
integrated latent virus. We used OM10.1 cells since they carry a latent
copy of HIV-1 and can be induced with the addition of TNF or other
cytokines (Agbottah et al., 2006). We transfected OM10.1 cells witheither TAALD or LAALS peptides (0.1, 1, 3 μM) and then treated cells
with TNF-α for 2 h. Samples were kept at 37 °C for 4 days prior to RT
assay. As controls, we used no peptide treatment, just TNF-α treat-
ment or increasing concentration of cdk2 inhibitor Cyc202. Results are
shown in Fig. 6A where increasing concentration of LAALS, but not
TAALD, resulted in more than 90% suppression of HIV-1 in a con-
centration dependent manner (lanes 6–8). Importantly, these pep-
tides had no appreciable toxicity effect even up to 5 μM in a trypan
blue assay in CEM cells after 4 days (panel B). As expected, positive
control reagents such as a Nocodazole or Hydroxyurea treatment
of the cells inhibited cell growth, ultimately leading to cell death
Fig. 7. Presence of various cdk complexes on HIV-1 LTR. Chromatin-immunoprecipitation (ChIP) was used to detect presence of cdk2, 4 or 9 on the HIV-1 promoter in the presence of
either wild type or LAALS peptide inhibitors. Both OM10.1 (day 4) and infected PBMCs (day 12) cells were processed for ChIP assay. Speciﬁc anti-cdk antibodies (10 μg/reaction) were
used to immunoprecipitate the chromosomal DNA followed by PCR for presence of LTR/Gag sequence. Lane 1 is the input DNA prior to IP, and lane 2 serves as negative control without
antibody treatment. Lanes 3, 8 and 13 are PCR products from cdk2 IP; lanes 4, 9, and 14 are from cdk9 IP; and lanes 5, 10 and 15 are from cdk4 IP.
315R. Van Duyne et al. / Virology 376 (2008) 308–322(panel B). Finally, we asked if these peptides could have an inhibitory
effect on HIV-1 in PBMC infected cells. Activated PBMCs were
transfected with pNL4 with or without the two peptides. As seen in
panel C, infection resulted in active viral production by Day 6 and 12.
Most cells did not grow or support viral replication by Day 18.
Importantly, the LAALS (1 μM), but not TAALD, peptide was capable of
suppressing viral activity in these PBMC infected cells. Collectively,Fig. 8. Replication of HIV-1 ADA and THA primary isolate in PBMCs isolated from Rag2−/−γ
and plated in a 96 well plate for viral infection. Cells were cultured at in RPMI 1640 medium c
L-glutamine (Invitrogen). Two strains of virus were used for infection. HIV-1ADA a macropha
infections. Samples were either treated with CSF-1, AZT, wild type or mutant Tat peptides, o
was from animals that did not receive stem cells but virus added in vitro. Supernatants werthese results suggest that the LAALS peptide is capable of inhibiting
HIV propagation in both cell lines and primary cells.
Possible dissociation of cdk from HIV-1 promoter in peptide treated cells
We have previously shown that one mechanism of peptide
inhibition in HIV-infected cells is to physically dissociate cdk awayc
−/− mice. Peripheral blood samples from sixteen week animals were collected, washed
ontaining FBS and treated with a mixture of streptomycin and penicillin antibiotics and
ge-tropic CCR5-using (R5) strains and THA/92/001, an NSI primary strain were used for
r Cyc202. Mock 1 was from animals that did receive stem cells but no virus, and Mock 2
e subsequently collected and used for the p24 assay.
Table 1
Effect of HIV inhibitors on in vivo replication of HIV-1 ADA in mice
Mouse
ID no.
HIV-infected
(ADA)
Treatment Viral RNA
copies
Viral DNA
copies
3⁎ + – b100 b100
4⁎ + – 1,237,925 855,109
5⁎ + – 836,676 401,664
6⁎ + – 574,730 988,111
7⁎ + AZT 14,379 168,450
8^ + AZT 26,892 190,347
9^ + AZT 80,587 177,420
10⁎ + Peptide (WT) 935,250 804,510
11⁎ + Peptide (WT) 743,099 938,553
12^ + Peptide (WT) 1,359,688 1,209,553
13^ + Peptide (WT) 1,690,319 1,857,336
14⁎ + Peptide (41/44) 58,477 640,653
15⁎ + Peptide (41/44) 28,105 750,772
16^ + Peptide (41/44) 103,266 1,800,841
17^ + Peptide (41/44) 87,392 1,736,217
18⁎ + Peptide (LAALS) 36,921 1,548,770
19⁎ + Peptide (LAALS) 48,750 1,254,929
20⁎ – – b100 b100
21^ – – b100 b100
Animal #3 did not receive any human stem cells, and animals #16 and 17 did not
receive HIV, but RPMI media as mock. (⁎) denotes Rag/γc animals and (^) denotes
NOD/SCID animals.
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immunoprecipitation (ChIP) assays to deﬁne molecules that are
present or absent on the HIV promoter after peptide treatment. We
therefore decided to perform similar experiments in the presence of
the newly modiﬁed peptide. Both OM10.1 (Day 4) and infected PBMCs
(Day 12) were cross linked and used for ChIP with anti-cdk2, anti-
cdk9, and anti-cdk4 (control) antibodies. Following the ChIP assays,
the recovered DNA was used in PCR with primers that span the LTR/
Gag region (Agbottah et al., 2006). Results in Fig. 7 indicate that when
cells were treated with no peptides or the control peptide (0.1 μM),
both cdk2 and cdk9 were present on the HIV promoter region in both
cell line and PBMC infected cells (lanes 3, 4, 8 and 9). Importantly, both
cdk2 and cdk9 were dissociated from the HIV promoter when using
LAALS (0.1 μM) peptide (lanes 13 and 14). Negative control cdk4 was
not present on the HIV promoter (lanes 5, 10 and 15). Collectively,
these results point to dissociation of the cdk2 and cdk9 away from the
HIV promoter in peptide treated cells.
Effect of peptide inhibitors on HIV-1 RNA production in a newly
developed mouse model
We have developed a mouse model where human cord blood stem
cells are implanted into immunodeﬁcient mice and allowed to re-
constitute an immune system in vivo. The double-mutant mice with
deleted recombinase activating gene 2 (RAG)-2 and common cytokine
receptor gamma chain (Rag2−/−γc−/−) has been seen by us and others to
be a viable option in reconstitution experiments. These Rag2−/−γc−/−
mice exhibit an alymphoid phenotype with no spontaneous tumor
formation and can be implanted with hematopoietic stem cells that
can be further enhanced by administration of exogenous human
cytokines (Kosco-Vilbois, 2004). A number of recent publications using
this strain as well as reconstitution in NOD/SCID mice with human
stem cells show a very promising path for a feasible HIV/AIDS animal
model (Baenziger et al., 2006; Berges et al., 2006; Gorantla et al., 2007;
Watanabe et al., 2007a,b; Zhang et al., 2007). In our preliminary
experiments, we found that mice tolerated a sub-lethal dose of 3.5 Gy
(to destroy any residual endogenous immune system) and despite
infertility, transplanted and non-transplanted animals showed no
obvious defects compared with non-irradiated controls. We ﬁrst
reconstituted newborn Rag2−/−γc−/− mice intrahepatically (i.h.) with
CD34+ cord blood cells and subsequently analyzed between four and
twenty-six weeks of age for presence of human CD45+ hematopoietic
cells. An increase in splenic and thymic cellularity was detectable, and
as expected all mice beyond eight weeks developedmesenteric lymph
nodes (Traggiai et al., 2004). The spleen, lymph node, and blood CD19+
cells expressed the IgM antigens. Mice beyond eight weeks developed
mesenteric lymph nodes, and showed enlarged spleens whereas
lymph nodes and enlarged spleens were never detected in non-
transplanted controls (data not shown).
We next asked whether cells from the transplanted animals could
indeed allow replication of HIV-1 in vitro. PBMCs from implanted
animals were used for in vitro infection of HIV-1 using the lab adapted
macrophage-tropic strain ADA and a primary isolate called THA/92/00.
This particular primary strain has previously been used by us for
infection of human PBMCs in vitro (Agbottah et al., 2005). Sixteenweek
peripheral blood sampleswere initially collected, processed to lyse red
cells and stored in liquid N2. After conﬁrmation that these animals
contained human hematopoietic cells, frozen mononuclear cells
(5×105) were thawed, washed and plated in a 96 well plate for viral
infection. Cells were cultured in RPMI medium containing FBS and
treated with a mixture of streptomycin and penicillin antibiotics and
L-glutamine. Infected cells were washed and subsequently treated
with either wild type or mutant Tat peptides (experimental), AZT, or
Cyc202 (controls). Supernatant samples were collected for the presence
of Gag p24 for up to 24 days. As a control, cells were allowed to dif-
ferentiate into mature macrophages in the presence of CSF-1 (M-CSF).Figs. 8A and B shows that ADA could effectively replicate in these cells
and that CSF-1 can slightly increase the viral titers in cells obtained
from animals. Also, these three different inhibitors including Tat
peptide (our initial 41/44 peptide), AZT and Cyc202 inhibited virus
replicationwhen infectingwith the ADA or the THA strain. The effects
of Tat peptide inhibitors and Cyc202 have previously been shown by
us (Agbottah et al., 2005). Collectively, these results imply that
transplantation of human CD34+ cells into Rag2−/−γc−/− mice allows
differentiation of cells into competent human cells necessary for HIV-
1 infection in vitro and the virus can be inhibited with Tat peptides or
drugs that target pre- or post-integration events.
Inhibition of HIV-1 RNA production with Tat peptide derivative in
transplanted Rag2−/−γc
−/− mice in vivo
To address whether HIV-1 could indeed replicate in these animals,
we used the ADA viral stock with ~100,000 TCID50/ml for our initial
infections into animals. Animals received virus alone and/or ~1000 µg/
ml of AZT at the time of injection. A volume of 0.3 ml was injected into
the intra-peritoneal region of anesthetized Rag2−/−γc−/− mice with a
blunt-tipped 30-gauge needle. Animals were infected twelve weeks
post-transplantation. Animals that received HIV-1 and stem cells
alone (Table 1; # 4, 5 and 6), showed a presence of viral RNA and
integrated DNA. Animals treated with inhibitors including AZT and Tat
peptide 41/44 showed a dramatic drop in viral RNA (Table 1; #7, 14
and 15). Both animals #3 and #20 served as negative controls and
showed no HIV-1 RNA or DNA in these animals. We also observed
similar inhibitory effects using LAALS peptide (animals #18 and 19). It
is important to note that, although we were not able to successfully
detect signiﬁcant p24 levels in the serum of these animals, we co-
cultivated (1:10 ratio) the infected PBMCs with human monocytes
(U937 and THP) and human T-cells (CEM, H9, Jurkat) cells in vitro and
found varying ng/ml quantities of HIV-1 Gag p24 in the supernatants
of both monocytes and T-cells (data not shown).
To further conﬁrm that the human stem cell transplantation could
indeed support HIV-1 ADA growth and inhibition in vivo, and that
these results were not an artifact of using this particular animal strain,
we decided to use another strain of mice for similar subsequent
studies. NOD/SCID mice (generous gift of Dr. Leonard Schultz, the
Jackson Lab) were irradiated three weeks after birth and transplanted
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Results of these studies showed a consistent pattern of viral inhibition
in AZT and Tat peptide treated animals (Table 1, #16 and 17). In-
terestingly, even though the transplantation efﬁciency at the time of
cell and serum harvest was fairly high (27–61%) for these animals, still
no reproducible levels of Gag p24 antigen could be detected in the
serum of these animals after twoweeks. However, both cell associated
HIV-1 DNA and RNA was detectable in these animals (Table 1).
Discussion
The development of alternative antiretroviral therapies is crucial to
the progression of HIV-1 treatment. Currently, this therapy involves
the use of agents from distinct classes of antivirals: protease in-
hibitors, transcriptase inhibitors, fusion inhibitors, and integrase
inhibitors. Recently, compounds interacting with Tat/TAR (or siRNA
against Tat) have also been studied which inhibit HIV replication in a
low micromolar range (Ammosova et al., 2006; Christensen et al.,
2007; Mukerjee et al., 2007). However, most current antiretroviral
therapies result in more drug resistant viral strains, poor inhibition,
and low efﬁciency.
Pharmacological cdk inhibitors (PCIs) are an attractive concept for
the next phase of antiretroviral therapies. Drugs that would target
various cdk/Cyclin complexes which are vital in controlling viral tran-
scription, replication, and progeny formation may allow for the
inhibition of virally-induced cell cycle progression and result in the
inhibition of viral transcription and replication. Artiﬁcial peptide
inhibitors have been developed, and have shown selectivity for cdks
through binding near the active site, however, in depth knowledge of
both substrate and kinase is needed in order to be effective.
Previously, we have shown success in mimicking the core domain
of the HIV-1 viral protein Tat sequence, and making simple alterations
in order to impart an inhibitory effect on HIV-1 gene expression
(Agbottah et al., 2006). The 41/44 peptide analog was found to act
upon the cdk2/Cyclin E interface, which through a series of
biochemical assays, was determined to be present on the HIV-1
promoter. In previous studies, a model for the interaction of cdk2/
Cyclin E on the viral promoter was established where in the presence
of TAR, Tat regulates this complex and is essential in phosphorylating
transcriptional machinery, including the RNAPII CTD. A model for the
peptide analog induced inhibition was also established, where the
binding of the peptide to cdk2 causes it to dissociate from the Cyclin
subunit, therefore inactivating the kinase and preventing activation of
transcription factors through phosphorylation. Here, we continued
these studies including additional peptides with varying efﬁcacies for
cdk2 inhibition and evaluate the inhibitory effects into an in vivo
model.
In this study, the initial Tat 41/44 double-mutant, TAALS, was
modiﬁed to include one additional point mutation to generate the
peptides indicated in Fig.1. Given the computationally derived binding
afﬁnities, the initial inhibition assay performed was meant to test the
in vitro inhibitory effects of each peptide. The cdk2/Cyclin E IPWestern
data in Fig. 2 indicated that peptides TAACS and LAALS showed the
highest degree of possible dissociation, and subsequently the greatest
inhibition of the kinase activity (Fig. 3). This in vitro data suggests that
not only are there varying degrees of speciﬁcity of each peptide for
binding to cdk2, as predicted, but the dissociation seen is also
indicative of loss of kinase activity. Interestingly, the two peptides
shown to dissociate the complex most successfully did not have the
highest predicted binding afﬁnity energy as compared to all the
predicted ligands. It is also important to mention that the two pep-
tides speciﬁcally bound to the unphosphorylated form of cdk2,
implying that the phosphorylated subunit has an induced conforma-
tional change, therefore closing the ligand binding site. These in vitro
studies were carried out using immunoprecipitated complexes, and
it is important to note that we have never observed a complete dis-sociation of the complex when using these Tat peptides. We trans-
fected these inhibitory peptides into proliferating cells to monitor the
level of apoptosis induced by inhibition of the cdk2/Cyclin E complex.
Complementary concentrations of inhibitors were used in the cell
cycle analysis as in the in vitro activity studies, and consequently
proved that the amounts of peptides needed to inhibit the complex for
HIV-1 transcription were not toxic to the cells.
The inhibitory peptide LAALS has thus far been the most adept at
dissociating and inhibiting cdk2/Cyclin E as well as conferring little
toxic effect on non-infected cells. We tested LAALS inhibitory effects
on a simulated viral promoter. The effectiveness of LAALS in sup-
pressing transcription of the HIV-1 LTR was monitored in Fig. 5.
Increasing concentrations of LAALS in the presence of Tat resulted in a
dramatic decrease in the LTR-CAT reporter activity as compared to the
wild type peptide. Fig. 5C indicates that the activity of LAALS is speciﬁc
for the HIV-1 promoter and not for HTLV (in the presence of Tax).
We tested the efﬁcacy of LAALS in inhibiting viral replication in a
latently infected cell line. Results in OM10.1 cells showed a decrease in
viral replication correlating with an increase in concentration of
LAALS treatment. This treatment exhibited an effect comparable to the
well known cdk inhibitor drug Cyc202, and more importantly, the
control peptide TAALD did not result in reduced viral replication.
Again, cell proliferationwas still not affected by this treatment. Fig. 6C
further conﬁrmed the drop in viral load by looking at the treatment of
infected PBMCs with LAALS and a control peptide. The PBMCs treated
with LAALS showed an overall decrease in viral load as compared to
untreated and control treated cells.
The data thus far has indicated and implied a change in protein–
protein interactions resulting in a lower amount of viral transcription
in the presence of the peptide LAALS. This has been inferred by activity
levels at the viral LTR as well as monitoring the levels of virus present.
It is well known that key cellular factors (i.e., NF-kB, Sp1 and cdk9)
interact with the viral LTR resulting in Tat activated transcription
which can be detected using ChIP assays. Fig. 7 shows a ChIP assay
where latently infected cells and PBMC infected cells were either
untreated, treatedwith control or LAALS peptides and screened for the
presence of cdk2, cdk9, and cdk4 at the LTR. No changes were seen
when cells were treated with the wild type peptide, however, in the
presence of LAALS, there was no pulldown of cdk2 or cdk9 in either
latent cells or PBMCs. Loss of cdk9 from the LTR in the presence of
LAALS is very interesting andmay prove to be signiﬁcant. It is possible
that the inhibition of cdk2/Cyclin E prevents a phosphorylation
event which is otherwise necessary for the recruitment/modiﬁcation
of p-TEFb or that the peptide has some homology to the cdk9/Cyclin
T interface site. Along these lines we have recently found that cdk9/
Cyclin T is a substrate for cdk2/Cyclin E complex and may in fact
enhance the auto-phosphorylation of cdk9 that is normally seen prior
to Tat activated transcription (S. Nekhai and F. Kashanchi, unpublished
data).
Finally, the current work utilizes a novel animal model that uses
reconstitution of the human immune system when implanting
irradiated mice with human CD34+ stem cells. A previous pioneering
report by the Manz group has indicated that the human T-cells were
observed in mouse secondary lymphoid organs which underwent a
number of post-thymic cell divisions as measured by TCR-rearrange-
ment excision circles (TRECs) (Traggiai et al., 2004). Inspired by these
results, and more recent similar publications (Baenziger et al., 2006;
Berges et al., 2006; Gorantla et al., 2007; Watanabe et al., 2007a,b;
Zhang et al., 2007) we injected CD34+ cord blood cells into sub-lethally
irradiated newborn Rag2−/−γc−/− mice and observed a signiﬁcant num-
ber of human CD45+ hematopoietic cells when using FACS analysis.
Our attempts to infect these cells ex-vivo and in vivo were successful
using either T- or lab adapted macrophage-tropic viruses. When using
the ADA and THA/92/00 viruses, we observed a healthy infection
in vitro and were able to follow virus replication up to 24 days.
These results were encouraging as they indicated that the in vivo
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HIV receptor/co-receptor pathway. However, to date we have not
expanded our virus repertoire and do not know if virus replication is
unique to these particular strains or can they be infected by a broad
range of HIV-1 clades. Future studies will determine the efﬁciency of
infection, level of pathogenesis, and whether certain viruses can
replicate better in the ex-vivo system as compared to the in vivo
model.
We were also encouraged by the inhibitor studies using AZT,
Cyc202, and Tat peptide inhibitors as these compounds reduced
detectable virus in the mouse model. Our in vivo infection studies in
the transplanted animals are the most exciting results. Our initial
injection of HIV orHIV+AZTutilized an i.p. route and seems to facilitate
viral entry into cells. As such, we were able to observe HIV infection in
these animals and a marked decrease of Gag DNA and RNA in AZT
treated cells, indicating that the virusmay be able to enter the cells and
go through the RT process followed by integration and subsequent
transcription. However, many factors, including better titration of
virus, peptides, and drugs, will have to be performed to obtain valid
viral kinetic data in vivo. Finally, wewere not able to successfully detect
p24 antigen levels in the serum of these animals; however upon co-
cultivation of infected cells, we were able to observe ng/ml quantities
of HIV-1 Gag in a tissue culture setting (data not shown). We believe
that this may be due to many reasons including possible low viral
production in vivo, rapid clearance of the virus within 24–48 h of
release, possible accumulation of virus in speciﬁc organs as opposed to
PBMCs, few rounds of viral replication, possible depletion of human T-
and monocytic cells, or differing viral replication kinetics between
tissue culture isolates and primary virus isolated from patients.
Ongoing future experiments will clearly deﬁne the limits of this
animal model and will determine the extent that the model could be
used to study peptide inhibitors, drugs, siRNA, or vaccine candidates.
Materials and methods
Computational modeling
Computational docking studies were carried out as previously
described by Agbottah et al. (2006). We took advantage of the existing
crystal structure of cdk2 to mimic binding of each of the Tat peptide
analogs to the cdk/Cyclin binding site. The cdk2 structure used was
obtained from the Protein Data Bank ID 1FIN (resolution 1.85 A°).
Docking was performed using the software AutoDock 3.0 with the
simulated annealing search algorithm. The receptor protein (cdk2)
was taken as rigid and the ligands (thewild type andmutant peptides)
as ﬂexible. All torsion angles were allowed to change (except those
about the peptide bond), giving 19 rotatable bonds for the wild type
peptide and 16 for the mutant TAALS. The annealing temperature was
reduced with a geometric scheme, and each docking run took about
2 h on a 2.8 GHz processor. A Linux computer cluster with 64 nodes
was employed for our simulation. For each docked ligand conforma-
tion, computer scripts were written to breakdown the total ligand–
receptor interaction energy by ligand atoms (this assists in ligand
optimization). To determine the binding site of the wild type and
mutant peptides on cdk2, binding energy per residue was calculated
for the low-energy docked conformations, and each cdk2 residue was
ranked by average energy for these conformations. To further exploit
this mechanism of cdk inhibition, we screened for other peptides that
can potentially target this pocket more effectively with stronger
binding afﬁnities. To this end, we performed molecular docking simu-
lations for all 95 possible singlemutants of TAALS while restricting the
allowed conﬁgurational space of these peptides to the local region
around this new binding pocket of cdk2 by TAALS. The simulations
resulted in 15 mutant variants of TAALS that have stronger binding
afﬁnities than that of TAALS, the top ﬁve of which are listed in Fig. 1
and are selected for further experimental studies.Peptide synthesis
All peptides used for this study were commercially synthesized
(SynBioSci, Livermore, CA) with the following sequences:
NH2-T-A-A-L-D-OH
NH2-T-A-A-L-E-OH
NH2-L-A-A-L-S-OH
NH2-T-A-A-C-S-OH
NH2-F-A-A-L-S-OH
NH2-T-A-A-L-S-OH
The purity of each peptide was analyzed by HPLC to greater than
98%. Mass spectral analysis was also performed to conﬁrm the identity
of each peptide as compared to the theoretical mass (Applied
Biosystems Voyager System 1042). Peptides were resuspended in
dH2O to a concentration of 1 mg/ml and stored at −70C. Peptides were
only thawed once prior to use for biochemical or in vivo experiments.
Cell culture
C81 is an HTLV-1-infected T-cell line that expresses Tax protein,
and CEM (12D7) is an uninfected human T-cell line established from
patients with T-cell leukemia. C81 and CEM cells were cultured in
RPMI 1640 containing 10% fetal bovine serum, 1% penicillin/strepto-
mycin, and 1% L-glutamine (Quality Biological) and were incubated in
a 5% CO2 incubator at 37 °C. Cells were cultured to conﬂuency and
pelleted at 4 °C for 15 min at 3,000 rpm. The cell pellets were washed
twice with 25 ml of phosphate-buffered saline (PBS) with Ca2+ and
Mg2+ (Quality Biological) and centrifuged once more. Cell pellets were
resuspended in lysis buffer (50 mM Tris–HCl, pH 7.5, 120 mM NaCl,
5 mM EDTA, 0.5% NP-40, 50 mM NaF, 0.2 mM Na3VO4, 1 mM DTT, one
complete protease cocktail tablet/50 ml) and incubated on ice for
20 min, with a gentle vortexing every 5 min. Cell lysates were trans-
ferred to Eppendorf tubes and were centrifuged at 10,000 rpm for
10 min. Supernatants were transferred to a fresh tube where protein
concentrations were determined using Bio-Rad protein assay (Bio-
Rad, Hercules, CA).
Size-exclusion chromatography
C81 cell lysate (30 mg/ml) was fractionated on a Superose 6 HR 10/
30 column (AmershamBiosciences, Piscataway, NJ) in Buffer D (20mM
HEPES (pH 7.9), 0.05M KCl, 0.2 mM EDTA, 0.5 mM PMSF, 0.05 DTT, and
20% Glycerol). Flow-through was collected at 0.5 ml for 50 fractions.
Every 10th fractionwas analyzed by immunoblotting for cdk2 in order
to determine the elution location of the cdk2/Cyclin E complex.
Immunoprecipitation
Cdk2 containing chromatography fractions (28–32) were pooled
together for immunoprecipitation. The pooled C81 extracts (250 μg
each) were combined with 10 μg/μl of each respective peptide.
Cyclin E antibody (Santa Cruz, sc-198) was added to each reaction
tube (10 μl, 2 μg), the reaction mixture was brought up to 500 μl with
TNE50+0.1% NP-40 (100 mM Tris, pH 8.0; 50 mM NaCl; 1 mM EDTA,
0.1% Nonidet P-40) and was allowed to incubate while rotating
overnight at 4 °C. α-IgG was added to extract as a negative control,
and an IP was performed in the absence of competing peptide, acting
as a positive control. The following day, 30 μl of a 30% Protein A & G
bead slurry (CalBioChem, La Jolla, CA) was added to each reaction
tube and allowed to incubate while rotating for 2 h at 4 °C. Samples
were spun and washed 2× with TNE300 + 0.1% NP-40 (100 mM Tris,
pH 8.0; 300 mM NaCl; 1 mM EDTA, 0.1% Nonidet P-40) and 1× with
TNE50+0.1% NP-40 to remove non-speciﬁcally bound proteins. 2×
Laemmli buffer was added to each sample and heated at 95 °C for
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PAGE gel to be used for both Western blots and kinase assays.
Cdk2 and Cyclin E were puriﬁed from lysates of SF9 insect cells
infected with baculoviruses producing cdk2 and Cyclin E. Brieﬂy, 1 ml
of cells (from 250 ml of culture) was lysed with 16 ml of lysis buffer
(50 mM Tris–HCl, pH 8.0, 10 mM 2-mercaptoethanol, 10% glycerol and
PMSF), homogenized on ice and centrifuged at 45,000 ×g for 1 h at
4 °C. Supernatant was loaded on Mono-Q 10/10 column (Amersham,
USA). Two separate cell cultures, one infected with cdk2-expressing
baculovirus and the other one infected with Cyclin E-expressing
baculovirus were used for puriﬁcation. The Mono-Q fractions contain-
ing cdk2 or Cyclin E weremixed 1:1 and loaded onto Superdex column
(Sephadex H200, Amersham, USA). Purity of cdk2/Cyclin E was
checked on 12% PAGE followed by Coomassie staining. We also
analyzed the Superdex fractions by immunoblotting with anti-cdk2
antibodies and assayed their enzymatic activity using histone H1 and
puriﬁed Tat proteins as substrates. Fractions containing cdk2/Cyclin E
were concentrated using Microcon tubes (Amicon, USA).
Western blots
Immunoprecipitated Cyclin E samples in the presence of Tat
peptides were probed for cdk2. IP samples separated on SDS/PAGE
gels were transferred to a nitrocellulose membrane via a constant
current of 70mA overnight. Themembranewas blockedwith a 3% BSA
solution in PBS containing 0.1% Tween-20, rocking for 2 h at 4 °C. A
1:1000 dilution of α-cdk2 antibody (Santa Cruz, sc-163) was added to
the blocking solution and incubated rocking overnight at 4 °C. The
membrane was washed with a fresh PBS+0.1% Tween-20 solution in
order to wash off any residual primary antibody solution. A 1:1000
dilution of α-rabbit secondary antibody was added to a fresh 3% BSA
solution in PBS+0.1% Tween-20 and incubated with the membrane,
rocking for 2 h at 4 °C. The membrane was washed 2× with PBS+0.1%
Tween-20 and 1× with PBS to remove any residual antibody. The
membranewas exposed to chemiluminescence reagent (Pierce) in the
dark for 5 min., and was developed using a Kodak Imager.
GST-cdk binding assay to peptide in vitro
GST-cdk2, cdk4, cdk9 and GST alone were expressed and puriﬁed
twice over Glutathione Sepharose beads. The elution and re-binding
dropped the non-speciﬁc background signiﬁcantly. Peptides (50 μg)
were allowed tobindvariouspuriﬁedbead-GSTproteins (2 μg) overnight
at 4 °C. Next day theywerewashedwith TNE50+0.01%NP-40 and eluted
with 20 μl of elution buffer (TNE50+0.01% NP-40+0.01% SDS). Following
centrifugation eluates were used for further analysis. Eluted peptide
samples were combined with MS washing buffer (50:50 Methanol:
Water+0.1% TFA) and loaded onto a Hamilton Gastight 250 μl syringe.
Samplesweremanually injected into an ESI-MS LCQDecaXPPlus Thermo
Finniganmass spectrometer at 10 μl/min and read throughanAPI source.
Spectra were normalized to the highest abundant mass peak and were
averaged over the course of injection. Data acquisition and peak analysis
were performed through theXcalibur software platforms. Data is shown
zoomed in on relevant m/z ranges.
Kinase assay
Immunoprecipitated Cyclin E samples in the presence of Tat
peptides were assessed for kinase activity. After the ﬁnal TNE50+0.1%
NP-40 wash, beads were washed with kinase buffer (50 mM HEPES,
10 mM MgCl2, 5 mM MnCl2, 1 mM DTT, 50 mM NaF, 0.2 mM Na3VO4
and one complete tablet of protease cocktail inhibitor/50 ml buffer) to
equilibrate the reaction. The indicated amount of Histone H1 was
added to each reaction tube alongwith the indicated amount of (γ-32P)
ATP (3000 Ci/mmol). Reactions were incubated at 37 °C for 30min and
stopped by the addition of 15 μl Laemmli buffer. The samples wereseparated by reducing SDS-PAGE on a 4-20% Tris–Glycine gel. Gels
were stained with Coomassie blue, destained, and then dried for 2 h.
Following drying, the gels were exposed to a PhosphorImager cassette
and analyzed utilizing Molecular Dynamic's ImageQuant Software.
Flow cytometry
Cell cycle analysis was performed on CEM cells either untreated or
treated with WT or Tat derived peptides. Cells were collected by low
speed centrifugation andwashed with PBS without Ca2+ andMg2+ and
ﬁxed with 70% ethanol. For ﬂuorescence-activated cell sorting (FACS)
analysis, cells were stained with a mixture of propidium iodide (PI)
solution (PBS with Ca2+ and Mg2+, 10 µg/ml RNase A, 0.1% Nonidet P-
40, and 50 µg/ml PI) for 30 min at room temperature prior to analysis.
The cells were acquired and analyzed using CELLQuest software (BD
Biosciences). Acquired FACS datawere analyzed byModFit LT software
(Verity Software House, Inc.).
CAT assay
Wild type LTR constructs from both HIV and HTLV-1 were elec-
troporated into CEM cells. Extracts were prepared for chlorampheni-
col acetyltransferase (CAT) assay. The cells were harvested, washed
once with phosphate-buffered saline (PBS) without Ca2+ and Mg2+,
pelleted, and resuspended in 150 µl of 0.25 M Tris (pH 7.8). The cells
were freeze-thawed three times with vortexing and then incubated
for 5 min at 68 °C followed by centrifugation. The supernatants were
transferred to 1.5-ml Eppendorf tubes. After one ﬁnal spin, the super-
natant was again transferred to 1.5-ml Eppendorf tubes, and the
protein concentration was determined. CAT assays were performed
with 25 µg of protein as described in Kashanchi et al., 2000.
ChIP assays
Ten million OM10.1 cells in log phase were ﬁrst electroporated
with peptides and then incubated for 2 h with or 5 μg/ml TNF-α to
induce transcription of latent proviral DNA. After 4 days, cells were
cross linked (1% formaldehyde, 10 min at 37 °C) and samples were
sonicated to reduce DNA fragments to 200–800 nt lengths for ChIP
assays. Infected PBMCs (Day 12) were also treated for ChIP analysis.
Speciﬁc cdk complexes were immunoprecipitated with appropriate
antibodies (10 μg/reaction). DNA sequences in the immunoprecipi-
tates were detected by PCR using primers speciﬁc for the HIV-1 LTR/
Gag (Agbottah et al., 2006).
Mice
A set of male and female Rag2−/−γc−/− mice were graciously donated
by Dr. Anton Berns (The Netherlands Cancer Institute). Subsequent
experiments utilized similar animals obtained from Dr. Ramesh
Akkina (Colorado State University). Both sets of animal have
previously been described and are identical to animals described in
the Traggiai et al. manuscript (Traggiai et al., 2004). A breeding colony
was successfully established at the GWUMC. All procedures and
practices associated with the use of Rag2−/−γc−/− mice was been
approved by the GWUMC Committee on Human Research and
Committee on Animal Research (IACUCC #007-4,5A1 and animal
assurance #A-3205-01). The GWUMC Committee on Animal Research
was charged with carrying out the regulations of the federal
government's Animal Welfare Act governing the care and use of
animals in research and instruction. The animals are housed in an
AAALAC-approved vivarium GWUMC (BSL3 facility). Animal housing
consisted of a Techniplast caging system and all changes were com-
pleted in a biosafety hood. Bedding, food and water were all
autoclaved. Animals in the vivarium were monitored almost daily
and project protocols were reviewed and approved by the University
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−/−γc
−/− animals.
The NOD/SCID mice (NOD.Cg-Prkdc^scid Il2rg^tm1Wjl/SzJ; Stock
Number: 005557) were kindly donated by Dr. Leonard Schultz from
the Jackson Laboratory Animal Resource Department. These mice
were maintained in an AAALAC-approved vivarium housed within
GWUMC's BSL-3 suite at all times. Ten three week old NOD/SCID pups
were sub-lethally irradiated at a dose of 3.5 Gy using a CS-137
irradiator. Twenty-four hours later, the mice were given a 100 μl intra-
peritoneal (IP) injection of 100,000 human CD34+ cord blood stem
cells. These stem cells were allowed to differentiate for three weeks
followed by infection with HIV-1. Each animal was given an IP
injection of virus, virus plus drug, peptides or RPMI media. Twoweeks
after infection, the mice were sacriﬁced and blood was collected
through cardiac puncture for further DNA and RNA analysis.
Human Stem cells
CD34 cells were either obtained from Cambrex Bio Science
Walkersville, Inc. (Gaithersburg, MD) or prepared by us using the
following method. Cells were separated using the CD34 MicroBead Kit
(Miltenyi Biotec, Auburn, CA). This kit formerly termed Direct CD34
Progenitor Cell Isolation Kit is a single-step labeling system which
allows for a fairly fast and easy isolation of CD34+ cells. By using direct
MicroBeads instead of an indirect labeling system, the washing step
during the labeling procedure is abolished and resulting cell loss is
avoided. CD34+ cells were isolated from pooled cord blood samples.
The CD34 MicroBead Kit contained FcR blocking reagent and
MicroBeads which were conjugated to the monoclonal mouse anti-
human CD34 antibody, QBEND/10. The CD34 antigen is a single
transmembrane glycoprotein which is expressed on human hemato-
poietic progenitor cells andmost endothelial cells. Fluorescent control
staining of magnetically labeled cells requires a monoclonal CD34
antibody recognizing an epitope other than QBEND/10, e.g. clone
AC136. All cells were washed with PBS prior to implantation.
FACS analysis for cells from animal studies
Samples (i.e, twenty-four weeks post-transplantation) were
collected from euthanized animals and blood, thymus, bone marrow,
mesenteric lymph nodes and spleen were collected from both
transplanted and non-transplanted animals. In most cases to obtain
peripheral blood cells, mice were bled from retro orbital venous sinus
under anesthesia. After euthanasia, single cell suspensions were
prepared from various organs and red cells were lysed in cold ACK
lysis buffer (NH4Cl 8.29 g/l, KHCO3 1.00 g/l, disodium EDTA 2H2O
0.0372 g/l, membrane ﬁltered, pH: 7.4±0.2, Osmolality: 290±5%
mOsm/kg H2O). Remaining cells were then spun, washed once in 2 ml
PBS and pelleted again. Samples were cross linked with 1 ml of 4%
paraformaldehyde to ﬁx cells and virus at room temperature for
10 min. Subsequently they were washed in 1 ml PBS/BSA/10% NMS
(normal mouse serum), spun, washed in 100 μl PBS/BSA/NMS and
added 20 μl of each antibody to cells. Samples were incubated in dark
at RT, added 1 ml PBS/BSA/NMS, spun, and resuspended in 500 μl of
PBS/BSA/NMS.
Lymph nodes, spleens and thymuses were cut in small pieces and
homogenized on a 70 µ strainer with a syringe plunger. Cell
homogenates were washed once with 30 ml of RPMI 1640 supple-
mented with 10% FCS, and once with RPMI 1640 alone, centrifuged
and stained with antibodies for ﬂow cytometric analysis. The
following surface markers were used: CD45–FITC, CD3–FITC, CD19–
FITC, CD34–FITC and CD14-APC and CD33-Cy5. Antibodies were
purchased from e-Bioscience except for CD34 (BD Bioscience, San
Jose, CA). These antibodies were chosen to identify subsets of
hematopoetic cells that may have derived from the transplant. Cells
were analyzed using a FACScalibur (Becton Dickinson Immunocyto-metry Systems). At least 200,000 cells were acquired from each
sample for FACS analysis.
In vitro infection of human cells
Sixteen weeks peripheral blood samples from animals were
collected, washed and platted for viral infection. After conﬁrmation
that these animals contained human hematopoietic cells, frozen
mononuclear cells (5×105) were thawed, washed and platted in a 96
well plate for viral infection. Cells were cultured at 37 °C in RPMI 1640
medium containing 10% fetal bovine serum (FBS) and treated with a
mixture of 1% streptomycin, penicillin antibiotics, and 1% L-glutamine
(Invitrogen, Carlsbad, CA). Two strains of virus were used for infection
for 2 h in vitro. HIV-1ADA is a macrophage-tropic CCR5-using (R5)
strains (Jacque et al., 2002; Schmidtmayerova et al., 1997) and THA/92/
001 is an NSI primary strain (Agbottah et al., 2005). ADA (2×105 cpm
of RT activity) and THA/92/001 (Thailand strain, subtype E envelope,
5 ng of p24 Gag antigen) were used for these initial infections. Both
viruses have previously been used by our group with successful
infection rates. Washed cells were subsequently either treated with
2 ng/ml CSF-1 (Sigma, St. Louis, MO), AZT (100 µg/ml), wild type or
mutant Tat peptides (100 nM), or Cyc202 (0.36 µM). Mock 1 was for
animals that did receive stem cells but no virus, and Mock 2 was for
animals that did not receive stem cells but virus added in vitro.
Supernatants were collected and used for detection of p24 antigens
(Agbottah et al., 2005).
In vivo infection of HIV-1 in Rag2−/−γc
−/− mice
Sixteen weeks post-transplantation animals were infected with
ADA strain (~100,000 TCID50/ml). Various animalswould receive virus
alone, virus plus ~1000 µg/ml of AZT, or various peptides at 3 mg/kg
using intrapertenial administration. To detect viral DNA in these
animals (data not shown) four weeks later, chromosomal DNA was
isolated from PBMCs and examined for presence of HIV-1 DNA. A total
of 0.1, 0.01, and 0.001 mg of total DNA were used in PCRs to amplify
both HIV and human HLA-speciﬁc sequences in parallel. The primers
used were SK38 (59-ATA ATC CAC CTA TCC CAG TAG GAG AAAT-39)
and SK39 (59-TTT GGT CCT TGT CTT ATG TCC AGA ATG C-39),
which ampliﬁes a 115-bp region of the HIV-1 Gag gene, and GH26
(59-GTGCTG CAG GTG TAA ACT TGT ACC AG-39) and GH27 (59-CAC
GGA TCCGGT AGC AGC GGT AGA GTT G-39), which ampliﬁes a 242-bp
region of HLA-DQ-a. Mutant Gag primers included SK38 M (59-ATA
ATC CACGACTTTGAGTAGGAGAAAT-39) and SK39M (59-TTTGGTCCT
CGATTTGAGTCC AGAATG C-39). Ampliﬁcation conditionswere 1min
of denaturation at 95 °C, 2 min of annealing at 55 °C, and 3 min of
extension at 72 °C for 35 cycles; followed by 7 min at 68 °C. Following
PCR, sampleswere runon2% agarose gels and EtBr stained for presence
of DNA products.
For virological analysis from these animals, both viral RNA and
DNA ampliﬁcation was used as previously described (Watanabe et al.,
2007a,b). Cell associated viral RNA (from 5×104) copy numbers were
measured using a real-time quantiﬁcation assay based on the TaqMan
system (Applied Biosystems, Foster City, CA). Cell associated viral RNA
was extracted and puriﬁed using a QIAamp Viral RNAMini Kit (Qiagen,
Valencia, CA). This kit can be used to isolates plasma RNA, cell culture
RNA, and cellular RNA. The RNA was subjected to reverse-transcrip-
tion and ampliﬁcation using a TaqMan one-step RT-PCR Master Mix
Reagents Kit (PE Biosystems) with HIV-1 Gag consensus primers
(forward, 5′-GGACA TCAAGCAGCCATGCAA-3′, and reverse, 5′-TGCT-
ATGTCACTTCCCCTTGG-3′) and an HIV-1 Gag consensus TaqMan probe
(FAM-5′-ACCATCAATGAGGAAGCTGCAG AA-3′-TAMRA). Probed pro-
ducts were quantitatively monitored by their ﬂuorescence intensity
with the ABI7300 Real-Time PCR system (PE Biosystems). To obtain
control RNA for quantiﬁcation, HIV-1 Gag RNA was synthesized using
T7 RNA polymerase and pKS460. Viral DNAwas extracted and puriﬁed
321R. Van Duyne et al. / Virology 376 (2008) 308–322using a QIAamp DNA Mini Kit (Qiagen). Determination of HIV-1 DNA
copy numbers was performed by real-time PCR assay with TaqMan
Master mixture (PE Biosystems). Primers (forward, 5′-GGCTAAC-
TAGGGAACCCACTG-3′; reverse, 5′ CTGCTAGAGATTTTCC ACACT-3′)
and probes (FAM-5′ TAGTGTGTGCCCGTCTG TTGTGTGAC-3′-TAMRA)
were designed for targeting the HIV-1 long terminal repeat region, R/
U5. The viral DNAwas quantiﬁed using LightCycler (Roche). Viral RNA
and DNA were calculated based on the standard curve of control RNA
and DNA. All assays were carried out in triplicate.
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